![](/img/cover-not-exists.png)
R01Phase II study of everolimus in combination with octreotide LAR as first line setting for patients with neuroendocrine tumors (I.T.M.O. study): a 5-years update
Bajetta, E., Catena, L., Pusceddu, S., Fazio, N., Blanco, G., Ricci, S., Aieta, M., Pucci, F., Sarno, I., Spada, F., Di Menna, G., Dottorini, L.Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv348.01
Date:
October, 2015
File:
PDF, 32 KB
english, 2015